Neonc Technologies President Acquires $25,950 in Stock

Insider buying activity signals confidence in the company's future prospects.

Apr. 12, 2026 at 9:34am

Got story updates? Submit your updates here. ›

A close-up, high-contrast black and white image of complex banking mechanisms and machinery, representing the institutional power and financial security of Neonc Technologies.An insider's view of the intricate machinery powering Neonc Technologies' financial operations, signaling confidence in the company's future.Los Angeles Today

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour purchased 5,000 shares of the company's stock in a transaction on April 9th, 2026. The shares were acquired at an average cost of $5.19 per share, totaling $25,950. This increased Heshmatpour's ownership stake in the company to 3,032,000 shares, valued at approximately $15.7 million.

Why it matters

Insider buying activity is often viewed as a positive signal, as it suggests company leadership has confidence in the firm's future performance and growth potential. Neonc Technologies is a biotechnology company developing novel treatments for central nervous system diseases, so this purchase could indicate optimism about the progress of its drug pipeline.

The details

Heshmatpour's purchase represents a 0.17% increase in his position. Neonc Technologies' stock opened at $5.44 on the day of the transaction, compared to a 52-week range of $3.20 to $12.99. The company's shares have a current consensus rating of 'Reduce' from Wall Street analysts.

  • The stock purchase occurred on Thursday, April 9th, 2026.

The players

Amir Heshmatpour

The president of Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

A biotechnology company developing novel treatments for central nervous system diseases.

Got photos? Submit your photos here. ›

The takeaway

This insider purchase by Neonc Technologies' president indicates optimism about the company's drug pipeline and future prospects, despite the stock's current 'Reduce' rating from Wall Street analysts. Investors will likely watch for any additional insider buying activity or updates on the company's clinical trials in the coming months.